Research Article: Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study
Introduction:
Hepatocellular carcinoma (HCC) ranks as the sixth most prevalent cancer and the third leading cause of cancer-related mortality globally. First-line treatments such as ablation, surgical resection, and liver transplantation are traditionally reserved for early-stage HCC. However, in China, an estimated %-% of patients unfortunately present with portal vein tumor thrombus (PVTT), a complication associated with a bleak prognosis, limiting their treatment options. , Furthermore, a high tumor burden typically predicts…
Read more